BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 8942634)

  • 1. Molecular modeling and design of invariant chain peptides with altered dissociation kinetics from class II MHC.
    Liang MN; Lee C; Xia Y; McConnell HM
    Biochemistry; 1996 Nov; 35(47):14734-42. PubMed ID: 8942634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CLIP-region mediated interaction of Invariant chain with MHC class I molecules.
    Powis SJ
    FEBS Lett; 2006 May; 580(13):3112-6. PubMed ID: 16678175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of residues in the class II-associated Ii peptide (CLIP) region of invariant chain that affect efficiency of MHC class II-mediated antigen presentation in an allele-dependent manner.
    Gautam AM; Yang M; Milburn PJ; Baker R; Bhatnagar A; McCluskey J; Boston T
    J Immunol; 1997 Sep; 159(6):2782-8. PubMed ID: 9300699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell recognition of flanking residues of murine invariant chain-derived CLIP peptide bound to MHC class II.
    Naujokas MF; Southwood S; Mathies SJ; Appella E; Sette A; Miller J
    Cell Immunol; 1998 Aug; 188(1):49-54. PubMed ID: 9743557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
    Stumptner P; Benaroch P
    EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
    Thayer WP; Ignatowicz L; Weber DA; Jensen PE
    J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutting edge: a single, essential hydrogen bond controls the stability of peptide-MHC class II complexes.
    McFarland BJ; Beeson C; Sant AJ
    J Immunol; 1999 Oct; 163(7):3567-71. PubMed ID: 10490947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invariant chain can bind MHC class II at a site other than the peptide binding groove.
    Wilson NA; Wolf P; Ploegh H; Ignatowicz L; Kappler J; Marrack P
    J Immunol; 1998 Nov; 161(9):4777-84. PubMed ID: 9794409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T cell recognition.
    Boehncke WH; Takeshita T; Pendleton CD; Houghten RA; Sadegh-Nasseri S; Racioppi L; Berzofsky JA; Germain RN
    J Immunol; 1993 Jan; 150(2):331-41. PubMed ID: 8093457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editing of the HLA-DR-peptide repertoire by HLA-DM.
    Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
    EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of invariant chain can cause an allele-dependent increase in the surface expression of MHC class I molecules.
    Reber AJ; Turnquist HR; Thomas HJ; Lutz CT; Solheim JC
    Immunogenetics; 2002 May; 54(2):74-81. PubMed ID: 12037599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diminished class II-associated Ii peptide binding to the juvenile dermatomyositis HLA-DQ alpha 1*0501/DQ beta 1*0301 molecule.
    Reed AM; Collins EJ; Shock LP; Klapper DG; Frelinger JA
    J Immunol; 1997 Dec; 159(12):6260-5. PubMed ID: 9550430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flexibility of the MHC class II peptide binding cleft in the bound, partially filled, and empty states: a molecular dynamics simulation study.
    Yaneva R; Springer S; Zacharias M
    Biopolymers; 2009 Jan; 91(1):14-27. PubMed ID: 18767126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A negatively charged anchor residue promotes high affinity binding to the MHC class II molecule I-Ak.
    Nelson CA; Viner NJ; Young SP; Petzold SJ; Unanue ER
    J Immunol; 1996 Jul; 157(2):755-62. PubMed ID: 8752926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DM-mediated release of a naturally occurring invariant chain degradation intermediate from MHC class II molecules.
    Stebbins CC; Peterson ME; Suh WM; Sant AJ
    J Immunol; 1996 Dec; 157(11):4892-8. PubMed ID: 8943393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invariant chain transmembrane domain trimerization: a step in MHC class II assembly.
    Dixon AM; Stanley BJ; Matthews EE; Dawson JP; Engelman DM
    Biochemistry; 2006 Apr; 45(16):5228-34. PubMed ID: 16618111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A general model of invariant chain association with class II major histocompatibility complex proteins.
    Lee C; McConnell HM
    Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8269-73. PubMed ID: 7667280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC class II molecules.
    Adams S; Albericio F; Alsina J; Smith ER; Humphreys RE
    Arzneimittelforschung; 1997 Sep; 47(9):1069-77. PubMed ID: 9342425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of HLA-DQ binding properties by differences in class II dimer stability and pH-dependent peptide interactions.
    Buckner J; Kwok WW; Nepom B; Nepom GT
    J Immunol; 1996 Dec; 157(11):4940-5. PubMed ID: 8943399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.
    Ghosh P; Amaya M; Mellins E; Wiley DC
    Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.